In Brief
Refine Search
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Biotechnology
US clinical-stage biotech Remix Therapeutics today announced a collaboration and license agreement with Swiss pharma giant Roche. 3 January 2024
Biotechnology
US clinical-stage immunotherapy specialist ImmunityBio yesterday announced an up to $320 million royalty financing and equity investment in the company by Oberland Capital. 3 January 2024
Biotechnology
The life sciences landscape has adapted in tandem with data management solutions over the past several years, attracting significant investment. However, these solutions lack the ability to rapidly address and complement existing pain points and previous investments with the latest technological innovations. 3 January 2024
Pharmaceutical
Gannex Pharma has presented positive interim results from a Phase II trial of its thyroid hormone receptor β (THRβ) agonist ASC41. 3 January 2024
Pharmaceutical
Shares in Longboard Pharmaceuticals have shot up following positive data from the PACIFIC study evaluating bexicaserin. 3 January 2024
Pharmaceutical
UK-based Arecor Therapeutics has announced the appointment of Dr Helen Parris as senior vice president, commercial and general manager of Tetris Pharma. 3 January 2024
Biotechnology
Early-stage UK-based biotech 4X Discovery Holdings has received a milestone payment of $11 million from AstraZeneca. 3 January 2024
Pharmaceutical
China and USA-based Allorion Therapeutics has entered into an exclusive option and global license agreement with UK pharma major AstraZeneca. 3 January 2024
Biotechnology
Shares of US neurogenetic focused biotech Voyager Therapeutics shot up 30% to $10.86 today, after it announced a capsid license agreement and strategic collaboration with Novartis. 2 January 2024
Pharmaceutical
Shares of Denmark-based Zealand Pharma dipped 4.9% to 355.00 kroner by late afternoon, on negative news from the US medicines regulator. 2 January 2024
Biotechnology
UK-based biotech Sareum Holdings saw its shares gain 18% to 70.00 pence by early afternoon after it announced that is co-development partner, the CRT Pioneer Fund (CPF), has entered into a development and commercialization licence agreement for SRA737 with a private biopharma company based in the USA. 2 January 2024
Biotechnology
Takeda Pharmaceutical has pulled the plug on a gene therapy collaboration with fellow Japanese drugmaker JCR Pharmaceuticals. 2 January 2024
Biotechnology
After decades without a breakthrough, scientists targeting the respiratory syncytial virus (RSV) have notched up three successes in a period of around a year. 2 January 2024
Pharmaceutical
From January 1, 2024, developers of new medicines can now submit applications via the UK Medicines and Healthcare products Regulatory Agency’s (MHRA) new, International Recognition procedure (IRP). 2 January 2024
Pharmaceutical
Privately-held Italian drugmaker Alfasigma has signed an agreement with Belgium’s Galapagos to acquire the Jyseleca (filgotinib) business. 2 January 2024
Biotechnology
British and American biotech Apollo Therapeutics has boosted its series C financing round by $33.5 million, bringing the total amount to $260 million. 2 January 2024
Pharmaceutical
China’s National Medical Products Administration (NMPA) has approved Japanese pharma major Takeda’s antiviral drug Livtencity (maribavir). 29 December 2023
Biotechnology
South Korean biotech LegoChem Biosciences has entered into a license agreement with Janssen Biotech, to develop and commercialize LCB84. 29 December 2023
Biotechnology
US biotech Iovance Biotherapeutics saw its shares drop more than 20% on Tuesday, after it revealed a setback with its clinical program for LN-145 TIL therapy in non-small lung cancer (NSCLC). 29 December 2023
Biotechnology
US oncology drug developer Oncternal Therapeutics took a 10% initial tumble after it revealed a patient in an early-stage trial of its ONCT-808, but closed the day up 18% at $0.59. 29 December 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze